Achieving Medication‐Free Remission in Patients With Juvenile Dermatomyositis
Open Access
- 20 December 2024
- journal article
- research article
- Published by Wiley in ACR Open Rheumatology
- Vol. 7 (1)
Abstract
Objective: Prognostic factors associated with medication discontinuation in children with juvenile dermatomyositis (JDM) remain largely elusive. We aim to identify the predictors of medication‐free remission (MFR) in children with JDM.Methods: In this retrospective study, patients diagnosed with JDM according to Peter & Bohan criteria and followed for ≥18 months at a tertiary care center from 2006 through 2022 were included. Data extracted included demographics, physical examination, laboratory results, and medications. MFR was defined as inactive JDM after discontinuation of all systemic immunosuppressives for ≥6 months, in line with international consensus guidelines for trials of therapies in idiopathic inflammatory myopathies. A two‐sided P < 0.05 was considered statistically significant.Results: Of 55 patients with JDM (63.6% female, age median [interquartile range (IQR)] 6 [3.5–12] years), 29 (52.7%) achieved MFR after a median (IQR) of 33 (22.5–55.2) months. MFR was more common in those who were younger at JDM diagnosis (median 5 vs 8 years, P = 0.008), had early resolution of disease activity (median 11 vs 18 months, P < 0.001), and presented with Gottron papules (χ2 = 5.25; P = 0.022) and elevated lactate dehydrogenase (χ2 = 4.82, P = 0.028). Diagnosis of JDM before 5 years old (odds ratio 4.5, 95% confidence interval [CI] 1.2–16.7) was the only predictor of MFR in our multivariate model (area under the curve 0.65, 95% CI 0.53–0.76).Conclusion: Half of our patients with JDM achieved MFR. Age at JDM diagnosis may be an important predictor of achieving MFR.Keywords
This publication has 33 references indexed in Scilit:
- Characterization of the biomarkers related to the clinical course and outcomes of juvenile dermatomyositisJournal of Microbiology, Immunology and Infection, 2022
- Early-onset juvenile dermatomyositis: A tertiary referral center experience and review of the literatureSeminars in Arthritis and Rheumatism, 2022
- Whole-body MR imaging in evaluation of children with juvenile dermatomyositisEuropean Journal of Radiology, 2022
- Updates on Juvenile Dermatomyositis from the Last Decade: Classification to OutcomesRheumatic Disease Clinics of North America, 2021
- Clinical features, muscle biopsy scores, myositis specific antibody profiles and outcome in juvenile dermatomyositisSeminars in Arthritis and Rheumatism, 2021
- Factors Associated With Clinical Remission of Skin Disease in DermatomyositisJAMA Dermatology, 2018
- Juvenile dermatomyositis: a tertiary center experienceClinical Rheumatology, 2017
- Juvenile Dermatomyositis: A 20-year Retrospective Analysis of Treatment and Clinical OutcomesPediatrics & Neonatology, 2015
- Complete and sustained remission of juvenile dermatomyositis resulting from aggressive treatmentArthritis & Rheumatism, 2009
- International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathiesArthritis & Rheumatism, 2005